

Mitchell S Buckley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4016852/publications.pdf>

Version: 2024-02-01

50
papers

1,361
citations

394421

19
h-index

361022

35
g-index

50
all docs

50
docs citations

50
times ranked

1719
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Hypotension Associated With Two Different Vasopressin Discontinuation Strategies in the Recovery Phase of Septic Shock. <i>Journal of Pharmacy Practice</i> , 2023, 36, 830-838.	1.0	1
2	Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. <i>Journal of Critical Care</i> , 2022, 67, 134-140.	2.2	11
3	Dexmedetomidine for Facilitating Mechanical Ventilation Extubation in Difficult-to-Wean ICU Patients: Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 925-936.	2.8	10
4	Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 466-476.	2.8	13
5	Clinical Pharmacistâ€œLed Impact on Inappropriate Albumin Utilization and Associated Costs in General Ward Patients. <i>Annals of Pharmacotherapy</i> , 2021, 55, 44-51.	1.9	7
6	Action Plan for Successful Implementation of Optimal ICU Pharmacist Activities: Next Steps for the Critical Care Pharmacist Position Paper. <i>Critical Care Medicine</i> , 2021, 49, e199-e200.	0.9	12
7	Characterizing Critical Care Pharmacy Services Across the United States. , 2021, 3, e0323.		30
8	Optimization of critical care pharmacy clinical services: A gap analysis approach. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2077-2085.	1.0	30
9	Benefits of Patient/Caregiver Engagement in Adverse Drug Reaction Reporting Compared With Other Sources of Reporting in the Inpatient Setting: A Systematic Review. <i>Journal of Patient Safety</i> , 2021, 17, e765-e772.	1.7	1
10	Development and application of quality measures of clinical pharmacist services provided in inpatient/acute care settings. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1601-1617.	1.0	10
11	Examination of critical care pharmacist work activities and burnout. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 554-569.	1.0	17
12	Clinical Pharmacistâ€œLed Impact on Inappropriate Albumin Use and Costs in the Critically Ill. <i>Annals of Pharmacotherapy</i> , 2020, 54, 105-112.	1.9	16
13	The SUP-ICU Trial: Does It Confirm or Condemn the Practice of Stress Ulcer Prophylaxis?. <i>Hospital Pharmacy</i> , 2020, 55, 96-101.	1.0	3
14	Adverse Hemodynamic Events Associated With Concomitant Dexmedetomidine and Propofol for Sedation in Mechanically Ventilated ICU Patients. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1536-1545.	2.8	16
15	Hyperoncotic Albumin Reduces Net Fluid Loss Associated With Hemodialysis. <i>Hospital Pharmacy</i> , 2020, 55, 130-134.	1.0	1
16	Authorsâ€™ Reply to Uysal and Colleaguesâ€™ Comment on: â€œEvaluation of Potential Drugâ€œDrug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysisâ€œ. <i>Drug Safety</i> , 2020, 43, 195-196.	3.2	1
17	Evaluation of Potential Drugâ€œDrug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2019, 42, 1035-1044.	3.2	36
18	Moderate to Severe Acute Respiratory Distress Syndrome Management Strategies: A Narrative Review. <i>Journal of Pharmacy Practice</i> , 2019, 32, 347-360.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock. <i>Pharmacotherapy</i> , 2019, 39, 382-398.	2.6	21
20	Trigger alerts associated with laboratory abnormalities on identifying potentially preventable adverse drug events in the intensive care unit and general ward. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 207-217.	2.4	8
21	Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or ceftazidime in the intensive care unit. <i>Journal of Critical Care</i> , 2018, 48, 32-38.	2.2	42
22	Concomitant vasopressin and hydrocortisone therapy on short-term hemodynamic effects and vasopressor requirements in refractory septic shock. <i>Journal of Critical Care</i> , 2017, 42, 6-11.	2.2	3
23	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. <i>Annals of Pharmacotherapy</i> , 2017, 51, 529-542.	1.9	5
24	Executive Summary: Clinical Practice Guideline: Safe Medication Use in the ICU. <i>Critical Care Medicine</i> , 2017, 45, 1546-1551.	0.9	3
25	Clinical Practice Guideline: Safe Medication Use in the ICU. <i>Critical Care Medicine</i> , 2017, 45, e877-e915.	0.9	75
26	Drug Class Combination Associated Acute Kidney Injury. <i>Annals of Pharmacotherapy</i> , 2016, 50, 953-972.	1.9	29
27	Stress Ulcer Prophylaxis. <i>Critical Care Medicine</i> , 2016, 44, 1395-1405.	0.9	70
28	Reply. <i>Annals of Pharmacotherapy</i> , 2016, 50, 520-520.	1.9	0
29	Correlation of Free and Total Phenytoin Serum Concentrations in Critically Ill Patients. <i>Annals of Pharmacotherapy</i> , 2016, 50, 276-281.	1.9	16
30	A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs. <i>Critical Care Medicine</i> , 2015, 43, 1612-1621.	0.9	30
31	Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management Program on Inappropriate Use in Hospitalized Patients. <i>American Journal of Medicine</i> , 2015, 128, 905-913.	1.5	63
32	Evaluation of an Automated Surveillance System Using Trigger Alerts to Prevent Adverse Drug Events in the Intensive Care Unit and General Ward. <i>Drug Safety</i> , 2015, 38, 311-317.	3.2	16
33	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2014, 9, 71.	4.7	9
34	Interpatient Variability in Dexmedetomidine Response: A Survey of the Literature. <i>Scientific World Journal</i> , 2014, 2014, 1-12.	2.1	38
35	A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. <i>Pharmacotherapy</i> , 2014, 34, 279-290.	2.6	64
36	An evidence based systematic review of remifentanyl associated opioid-induced hyperalgesia. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 587-603.	2.4	42

#	ARTICLE	IF	CITATIONS
37	Clinical and Economic Evaluation of an Evidence-Based Institutional Epoetin-Utilization Management Program. <i>Clinical Therapeutics</i> , 2013, 35, 294-302.	2.5	10
38	Impact of a Clinical Pharmacy Admission Medication Reconciliation Program on Medication Errors in "High-Risk" Patients. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1599-1610.	1.9	83
39	Conivaptan for Treatment of Hyponatremia in Neurologic and Neurosurgical Adults. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1194-1200.	1.9	15
40	Combination therapy in the management of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2013, 67, 13-23.	1.7	16
41	Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1047-1051.	1.0	1
42	A Real-World, Multicenter Assessment of Drugs Requiring Weight-Based Calculations in Overweight, Adult Critically Ill Patients. <i>Scientific World Journal</i> , The, 2013, 2013, 1-9.	2.1	12
43	A critical evaluation of clinical decision support for the detection of drug-drug interactions. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 871-882.	2.4	99
44	Pharmacokinetic evaluation of ambrisentan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 371-380.	3.3	15
45	Hypertonic Saline, Electrolytes, and Insulin. , 2011, , 139-151.		0
46	Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. <i>Critical Care Medicine</i> , 2010, 38, S253-S264.	0.9	97
47	Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically Ill Adults. <i>Pharmacotherapy</i> , 2010, 30, 728-740.	2.6	33
48	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 151.	2.5	22
49	Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit*. <i>Pediatric Critical Care Medicine</i> , 2007, 8, 145-152.	0.5	94
50	Fish Oil Interaction with Warfarin. <i>Annals of Pharmacotherapy</i> , 2004, 38, 50-53.	1.9	107